'Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease,' said Frank Luppino, Chief Executive Officer of Remedium Bio. 'We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development.'.
“Lifespan Vision Ventures 与我们一样坚信，持久疗法具有从根本上改善慢性疾病治疗的潜力。”Remedium Bio 首席执行官 Frank Luppino 表示。“我们很高兴由他们领投我们的 A 轮融资，并欢迎 Harry Robb 加入我们的董事会，与此同时，我们将推进我们的技术平台，拓展产品管线，并为首次人体临床试验做好准备。”